Unity Biotechnology(UBX.US)

Last Updated 19:00:00 ET
longbridge loading

Uni-Bio Science Revamps Share Option Scheme Ahead of 2026 Expiry

Tip Ranks·
US
UBX
0.00%
US
VHT
+0.35%
US
LABU
+11.45%
Tip Ranks·
US
UBX
0.00%
US
VHT
+0.35%
US
LABU
+11.45%

UniXell’s Novel Epilepsy Therapy Is First of Its Kind to Enter Clinical Trials in Both China, US

Yicai·
US
UNBX
0.00%
US
BIB
+4.03%
US
BBH
+0.68%
Yicai·
US
UNBX
0.00%
US
BIB
+4.03%
US
BBH
+0.68%

Uni-Bio Science Flags Family Shareholding Reshuffle With No Market Impact

Tip Ranks·
US
SBIO
+3.67%
SH
513060
-0.38%
US
IXJ
+0.36%
Tip Ranks·
US
SBIO
+3.67%
SH
513060
-0.38%
US
IXJ
+0.36%

uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies

Pharmaceutical Technology·
US
BIB
+4.03%
SZ
159892
-0.71%
US
IBB
+2.11%
Pharmaceutical Technology·
US
BIB
+4.03%
SZ
159892
-0.71%
US
IBB
+2.11%

Duality Biotherapeutics Reshapes Board and Finance Leadership to Back R&D Strategy

Tip Ranks·
US
PBE
+1.37%
US
IHE
+0.82%
SZ
159837
-0.22%
Tip Ranks·
US
PBE
+1.37%
US
IHE
+0.82%
SZ
159837
-0.22%

Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy

Unusual Whales·
US
XBI
+3.89%
US
FBT
+1.89%
US
UBX
0.00%
Unusual Whales·
US
XBI
+3.89%
US
FBT
+1.89%
US
UBX
0.00%

Unity Biotechnology Files Dissolution Certificate Amid Cost-Cutting

Tip Ranks·
US
UBX
0.00%
Tip Ranks·
US
UBX
0.00%

Unity Biotechnology Approves Company Liquidation Plan

Tip Ranks·
US
UBX
0.00%
Tip Ranks·
US
UBX
0.00%
© 2026 Longbridge｜Disclaimer